Drug intelligence / Profile preview

interleukin-2 modified Renca cells

Development stage: Preclinical
Modality: Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

Interleukin-2 modified Renca cells are a type of tumor vaccine consisting of Renca renal cell carcinoma cells genetically engineered to express and produce interleukin-2 (IL-2). These modified cells are used in preclinical studies, specifically in a mouse model of pulmonary metastasis, to elicit an antitumor immune response. The production of IL-2 by the tumor cells aims to enhance local and systemic immunity against the tumor, and has shown synergistic effects when combined with local radiation therapy.

Other names: Renca/IL-2

Targets

IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on interleukin-2 modified Renca cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on interleukin-2 modified Renca cells.

Explore the full profile